KR20110038159A - 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 - Google Patents

사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 Download PDF

Info

Publication number
KR20110038159A
KR20110038159A KR1020117004842A KR20117004842A KR20110038159A KR 20110038159 A KR20110038159 A KR 20110038159A KR 1020117004842 A KR1020117004842 A KR 1020117004842A KR 20117004842 A KR20117004842 A KR 20117004842A KR 20110038159 A KR20110038159 A KR 20110038159A
Authority
KR
South Korea
Prior art keywords
benzamide
pyridin
thiazol
alkyl
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117004842A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 에스. 멜빈
마이클 그라우페
찬드라세카르 벤카타라마니
후안 에이. 게레로
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20110038159A publication Critical patent/KR20110038159A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020117004842A 2008-07-28 2009-07-28 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 Withdrawn KR20110038159A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8408108P 2008-07-28 2008-07-28
US61/084,081 2008-07-28

Publications (1)

Publication Number Publication Date
KR20110038159A true KR20110038159A (ko) 2011-04-13

Family

ID=40996551

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117004842A Withdrawn KR20110038159A (ko) 2008-07-28 2009-07-28 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물

Country Status (11)

Country Link
US (2) US8088771B2 (enExample)
EP (1) EP2326622A1 (enExample)
JP (2) JP2011529504A (enExample)
KR (1) KR20110038159A (enExample)
CN (1) CN102123987A (enExample)
AU (1) AU2009276699A1 (enExample)
BR (1) BRPI0916713A2 (enExample)
CA (1) CA2731323A1 (enExample)
MX (1) MX2011001090A (enExample)
NZ (1) NZ590747A (enExample)
WO (1) WO2010014611A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002534A1 (en) * 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
TW200922564A (en) * 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
JP2012501344A (ja) 2008-08-29 2012-01-19 トレヴェンティス コーポレイション アミロイド症を治療する組成物及び方法
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US9003783B2 (en) * 2010-09-30 2015-04-14 Electro-Motive Diesel, Inc. Burner arrangement for a two-stroke locomotive diesel engine having an exhaust aftertreatment system
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
CN102838625B (zh) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN103814017A (zh) 2011-07-15 2014-05-21 巴斯夫欧洲公司 杀真菌的苯基烷基取代的2-[2-氯-4-(4-氯苯氧基)苯基]-1-[1,2,4]三唑-1-基乙醇化合物
PE20140837A1 (es) 2011-07-15 2014-07-10 Basf Se Compuestos fungicidas 2-[2-cloro-4-(4-cloro-fenoxi)-fenil]-1-[1,2,4]triazol-1-il-etanol alquilo sustituidos
KR20140080482A (ko) 2011-08-15 2014-06-30 바스프 에스이 살진균 치환된 1-｛2-［2-할로-4-(4-할로겐-페녹시)-페닐］-2-알콕시-3-메틸-부틸｝-1h-［1,2,4］트리아졸 화합물
MX2014000511A (es) 2011-08-15 2014-02-19 Basf Se Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-etoxi-etil}-1h-[1,2,4]triazol sustituidos.
CN103732581B (zh) 2011-08-15 2016-05-18 巴斯夫欧洲公司 杀真菌的取代的1-{2-[2-卤代-4-(4-卤代苯氧基)苯基]-2-炔氧基乙基}-1h-[1,2,4]三唑化合物
BR112014011223A8 (pt) 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
MX353446B (es) 2011-11-23 2018-01-12 Novartis Ag Formulaciones farmaceuticas.
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
MD4635C1 (ro) 2013-10-14 2020-01-31 Eisai R&D Management Co., Ltd. Compuşi de chinolină substituiţi selectiv
WO2015057655A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
MX2017005663A (es) 2014-10-31 2018-03-01 Abbvie Sarl Tetrahidropiranos sustituidos y metodo de uso.
ES2927352T3 (es) * 2017-01-10 2022-11-04 Cstone Pharmaceutical Suzhou Co Ltd Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos
WO2019027855A1 (en) * 2017-08-02 2019-02-07 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
JP7250422B2 (ja) * 2017-12-28 2023-04-03 東京応化工業株式会社 レジスト組成物、及びレジストパターン形成方法
IL312674A (en) * 2018-01-29 2024-07-01 Merck Patent Gmbh GCN2 inhibitors and uses thereof

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2218660T3 (es) 1996-01-16 2004-11-16 Bristol-Myers Squibb Company Inhibidores aromaticos conformacionalmente restringidos de la proteina de transferencia de trigliceridos microsomales y procedimiento.
US20040006011A1 (en) 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
CN1308327C (zh) 2000-04-27 2007-04-04 安斯泰来制药有限公司 咪唑并吡啶衍生物
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002026712A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. Quaternary amines and related inhibitors of factor xa
WO2002034748A1 (fr) 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
SE0100569D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
CA2442654A1 (en) 2001-04-10 2002-10-10 Transtech Pharma, Inc. Probes, systems, and methods for drug discovery
PL366827A1 (en) 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7244740B2 (en) 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AU2002352663B2 (en) 2001-11-13 2007-06-21 Axys Pharmaceuticals, Inc. Cyanoalkylamino derivatives as protease inhibitors
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
JP2003313126A (ja) 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
US20040034084A1 (en) 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
GB0212049D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
CA2388358A1 (en) 2002-05-31 2003-11-30 Voiceage Corporation A method and device for multi-rate lattice vector quantization
JP3725105B2 (ja) * 2002-08-30 2005-12-07 株式会社東芝 二次電池の過放電防止回路及び二次電池の過放電防止法
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006503082A (ja) 2002-10-17 2006-01-26 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US20040087642A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20040092568A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
EP1565446A1 (en) 2002-11-28 2005-08-24 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US7135493B2 (en) * 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2004076452A1 (en) 2003-02-26 2004-09-10 Merck Sharp & Dohme Limited 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
AU2004220648B2 (en) 2003-03-06 2010-09-16 Boehringer Ingelheim Animal Health USA Inc. Antiprotozoal imidazopyridine compounds
ES2328819T3 (es) 2003-04-07 2009-11-18 Pharmacyclics, Inc. Hidroxamatos como agentes terapeuticos.
US20050187266A1 (en) 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
WO2004092145A1 (en) 2003-04-15 2004-10-28 Pfizer Inc. Alpha substituted carboxylic acid as ppar modulators
US20050234066A1 (en) 2004-04-15 2005-10-20 Agouron Pharmaceuticals, Inc. Alpha substituted carboxylic acids
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
JP2007510671A (ja) 2003-11-06 2007-04-26 セルジーン・コーポレーション アスベスト関連疾患および障害の治療および管理のための、ｊｎｋ阻害剤の使用方法およびそれを含む組成物
US7524851B2 (en) 2003-12-05 2009-04-28 Robert Bosch Gesellschaft Fur Medizinische Forschung (Rbmf) Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy
WO2005060571A2 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Antiprotozoal imidazopyridine compounds
US7671181B2 (en) 2004-01-16 2010-03-02 Merck Sharp & Dohme Corp. Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
KR101258504B1 (ko) * 2004-03-26 2013-04-26 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
NZ550114A (en) 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
CA2564568A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
US20070225293A1 (en) 2004-04-23 2007-09-27 Ab Science Use of C-Kit Inhibitors for Treating Fibrosis
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
EP1758654A1 (en) 2004-04-23 2007-03-07 AB Science Use of c-kit inhibitors for treating plasmodium related diseases
TW200613307A (en) * 2004-05-17 2006-05-01 Tibotec Pharm Ltd 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones
CA2566104A1 (en) 2004-05-18 2005-12-01 Ab Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
AU2005266312C1 (en) 2004-07-28 2011-06-16 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006044509A2 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
AU2005309732A1 (en) 2004-11-23 2006-06-01 Celgene Corporation JNK inhibitors for treatment of CNS injury
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
MX2007007272A (es) 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
JP2008527031A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なピロロピリジン誘導体
CA2600860A1 (en) * 2005-03-09 2006-09-21 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
JP4528918B2 (ja) 2005-06-21 2010-08-25 学校法人 関西大学 カルボキサミド誘導体
US20060293320A1 (en) 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
US20080207572A1 (en) 2005-07-14 2008-08-28 Ab Science Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
US20100069387A1 (en) 2005-09-07 2010-03-18 Palmer Stephen S IKK Inhibitors for the Treatment of Endometriosis
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
AR058073A1 (es) 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
ITMI20060296A1 (it) 2006-02-17 2007-08-18 Alberto Lodolo Dispositivo di intercettazione multifunzionale
EP1996233A2 (en) 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
JP2009535333A (ja) 2006-04-26 2009-10-01 メルク エンド カムパニー インコーポレーテッド 二置換アニリン化合物
WO2009002534A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds

Also Published As

Publication number Publication date
US20120045412A1 (en) 2012-02-23
AU2009276699A1 (en) 2010-02-04
BRPI0916713A2 (pt) 2015-11-10
NZ590747A (en) 2012-11-30
MX2011001090A (es) 2011-03-15
JP2014098002A (ja) 2014-05-29
CA2731323A1 (en) 2010-02-04
US8198299B2 (en) 2012-06-12
EP2326622A1 (en) 2011-06-01
US8088771B2 (en) 2012-01-03
JP2011529504A (ja) 2011-12-08
US20100022543A1 (en) 2010-01-28
WO2010014611A1 (en) 2010-02-04
CN102123987A (zh) 2011-07-13

Similar Documents

Publication Publication Date Title
KR20110038159A (ko) 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
JP5640006B2 (ja) ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤
JP5640005B2 (ja) Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
US20110052527A1 (en) Imidazopyridinyl thiazolyl histone deacetylase inhibitors
US7687527B2 (en) Compounds for the treatment of inflammatory disorders
AU2002334205B2 (en) Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US8178553B2 (en) Compounds for the treatment of inflammatory disorders
EP2468717B1 (en) Heterocyclic Amide Compounds Useful as Kinase Inhibitors
WO2010009166A1 (en) Oxindolyl inhibitor compounds
JP2016518316A (ja) Ｍｋ２阻害剤およびそれらの使用
US20120040998A1 (en) 2-alkyl piperidine mglur5 receptor modulators
CN106573907A (zh) 新颖的喹啉衍生物及其用于神经退化性疾病的用途
CA2694359A1 (en) Novel heterocyclic compounds as mglu5 antagonists
US8450355B2 (en) Compounds for the treatment of inflammatory diseases
AU2003217433A1 (en) Substituted pyridinones as modulators of p38 map kinase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid